Imfinzi is specifically approved for adults with biliary tract cancer that has spread to nearby tissues (locally advanced) or other areas of the body (metastatic).

Doctors performed a transplant of organs from a deceased four-year-old girl in Kyiv under Russian attack. The procedure saved ...

Abstract and Introduction Background: The presence of infective microorganisms in the bilio-pancreatic tract is believed to be important in both the onset and outcome of acute biliary pancreatitis.

"Biliary tract cancer is comparatively rare, but it's aggressive and spreads fast. Our accrual of more than 450 patients in a little more than two years really shows there is a need for new ways ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

Background and methods Biliary tract cancer is a heterogenous group of malignancies that includes gallbladder cancer, extrahepatic cholangiocarcinoma and intrahepatic cholangiocarcinoma.

Biliary tract infections (BTI), often linked to structural abnormalities like bile duct stones, pose significant treatment challenges due to drug-resistant bacteria like Pseudomonas aeruginosa ...

Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...

Background and methods Biliary tract cancer is a heterogenous group of malignancies, which include gallbladder cancer, extrahepatic cholangiocarcinoma and intrahepatic cholangiocarcinoma.

One of the deadliest forms of cancer is biliary tract cancer. Only one in three patients diagnosed with the disease is operable. The rest must settle for life-sustaining treatment.

The FDA on Wednesday granted accelerated approval to zanidatamab (Ziihera), a bispecific antibody, for pretreated HER2-positive biliary tract cancer.

Today we finally heard the data from the much-awaited abstract, examining gemcitabine, cisplatin, and Abraxane as compared to gemcitabine and cisplatin in first-line biliary tract cancers. This ...